Cynata Therapeutics (ASX: CYP) — Company Overview, News & Financial Data
Cynata Therapeutics is a clinical-stage biotechnology company focused on developing cell-based therapies using proprietary stem cell platform technology.
Cynata Therapeutics
Cynata Therapeutics is a clinical-stage biotechnology company focused on developing cell-based therapies using proprietary stem cell platform technology. The platform utilizes induced pluripotent stem cell technology to manufacture mesenchymal stem cells derived from a single donor, designed to deliver scalable and consistent cell manufacturing. Cynata Therapeutics advances a pipeline of therapeutic candidates targeting inflammatory, vascular, and autoimmune conditions. Its key clinical and development programs focus on conditions including acute graft-versus-host disease, diabetic foot ulcers, osteoarthritis, and kidney transplantation complications.
Snapshot
Operations
Products and/or services of Cynata Therapeutics
- Stem Cell Manufacturing Platform: Utilizes induced pluripotent stem cell technology to generate allogeneic mesenchymal stem cells from a single donor, providing uniform, scalable, and reproducible cell production for off-the-shelf therapeutic applications across multiple disease indications.
- Acute Graft-Versus-Host Disease Program: Clinical-stage therapeutic development using off-the-shelf stem cells to treat severe acute graft-versus-host disease, an immune reaction occurring after bone marrow transplants, focusing on immune modulation and survival outcomes.
- Osteoarthritis Therapeutic Program: Clinical evaluation of stem cell candidates administered via intra-articular injection to preserve cartilage structure, reduce localized joint inflammation, and improve physical function in patients suffering from knee osteoarthritis.
- Diabetic Foot Ulcer Therapy: Clinical trial program investigating topical stem cell administration to stimulate localized vascularization, accelerate tissue regeneration, and resolve non-healing chronic diabetic foot ulcers in patients with underlying vascular disease.
- Kidney Transplantation Immunotherapy: Preclinical and clinical development of cellular therapies designed to suppress immune rejection, improve graft survival, and preserve long-term organ function in patients undergoing renal transplantation procedures.
- Respiratory and Fibrotic Disease Pipeline: Early-stage research and development applying mesenchymal stem cells to treat severe pulmonary conditions, including idiopathic pulmonary fibrosis and acute respiratory distress syndrome, targeting tissue repair and inflammation reduction.
Cynata Therapeutics executive team
- Dr. Kilian Kelly Ph.D.MD, CEO & Director
- Dr. Jolanta AireyChief Medical Officer
- Dr. Mathias KrollChief Business Officer
- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary